Autologous hematopoietic stem cell transplantation in systemic lupus erythematosus patients with cardiac dysfunction: feasibility and reversibility of ventricular and valvular dysfunction with transplant-induced remission

Loh, Yvonne; Oyama, Yu; Statkute, Laisvyde; Traynor, Ann E.; Satkus, J; Quigley, Kathleen; Yaung, Kimberly; Barr, Walter G.; Bucha, Jurate; Gheorghiade, Mihai; Burt, Richard K.

doi:10.1038/sj.bmt.1705698

Cited by 18 publications

(14 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…54 The heart muscle has limited regeneration capacity, so stem cells offer the potential for regrowth of heart tissue and restoration of function. Several studies have been performed involving tracking magnetically labeled stem cells in order to follow their migration after transplantation in cardiac disease models.…”

Section: Applications Of Stem Cell Trackingmentioning

confidence: 99%

Tracking stem cells using magnetic nanoparticles

Berman

Walczak

Bulte

2011

WIREs Nanomed Nanobiotechnol

231

View full text Add to dashboard Cite

Stem cell therapies offer great promise for many diseases, especially those without current effective treatments. It is believed that noninvasive imaging techniques, which offer the ability to track the status of cells after transplantation, will expedite progress in this field and help to achieve maximized therapeutic effect. Today’s biomedical imaging technology allows for real-time, noninvasive monitoring of grafted stem cells including their biodistribution, migration, survival, and differentiation, with magnetic resonance imaging (MRI) of nanoparticle-labeled cells being one of the most commonly used techniques. Among the advantages of MR cell tracking are its high spatial resolution, no exposure to ionizing radiation, and clinical applicability. In order to track cells by MRI, the cells need to be labeled with magnetic nanoparticles, for which many types exist. There are several cellular labeling techniques available, including simple incubation, use of transfection agents, magnetoelectroporation, and magnetosonoporation. In this overview article, we will review the use of different magnetic nanoparticles and discuss how these particles can be used to track the distribution of transplanted cells in different organ systems. Caveats and limitations inherent to the tracking of nanoparticle-labeled stem cells are also discussed.

show abstract

Section: Applications Of Stem Cell Trackingmentioning

confidence: 99%

Tracking stem cells using magnetic nanoparticles

Berman

Walczak

Bulte

2011

WIREs Nanomed Nanobiotechnol

231

View full text Add to dashboard Cite

show abstract

“…Additionally, a 5-year post-transplant follow-up study of this same patient cohort demonstrated a trend towards improved lung function parameters, such as the diffusing capacity of lung for carbon monoxide (DLCO) [19], while a more recent clinical trial showed that, in patients with scleroderma, stem cell transplantation can prevent the development of pulmonary hypertension [20]. Similar disease remission following HSCT has been noted in patients with pulmonary hypertension secondary to systemic lupus erythematosus [21,22]. Finally, in a case report of a patient with treatment-refractory sickle cell anemia, reversal of precapillary pulmonary hypertension was found upon undergoing haploidentical non-myeloablative peripheral blood stem cell transplantation [23].…”

Section: Pulmonary Hypertension and Myeloid Cell Disordersmentioning

confidence: 87%

Myeloid-Derived Suppressor Cells and Pulmonary Hypertension

Bryant

Mehrad

Brusko

et al. 2018

IJMS

View full text Add to dashboard Cite

Myeloid–derived suppressor cells (MDSCs) comprised a heterogeneous subset of bone marrow–derived myeloid cells, best studied in cancer research, that are increasingly implicated in the pathogenesis of pulmonary vascular remodeling and the development of pulmonary hypertension. Stem cell transplantation represents one extreme interventional strategy for ablating the myeloid compartment but poses a number of translational challenges. There remains an outstanding need for additional therapeutic targets to impact MDSC function, including the potential to alter interactions with innate and adaptive immune subsets, or alternatively, alter trafficking receptors, metabolic pathways, and transcription factor signaling with readily available and safe drugs. In this review, we summarize the current literature on the role of myeloid cells in the development of pulmonary hypertension, first in pulmonary circulation changes associated with myelodysplastic syndromes, and then by examining intrinsic myeloid cell changes that contribute to disease progression in pulmonary hypertension. We then outline several tractable targets and pathways relevant to pulmonary hypertension via MDSC regulation. Identifying these MDSC-regulated effectors is part of an ongoing effort to impact the field of pulmonary hypertension research through identification of myeloid compartment-specific therapeutic applications in the treatment of pulmonary vasculopathies.

show abstract

“…Recently, the Chicago group published a retrospective analysis of a subgroup of 13 patients with cardiac dysfunction who underwent auto-HSCT for systemic lupus erythematosus. Interestingly, the group noted that, rather than worsening, cardiac function either remained stable or, in several cases, improved after auto-HSCT in patients who achieved disease remission [26]. Similarly, the Chicago group reported in an earlier analysis of 34 patients that disease remission achieved following auto-HSCT resulted in improved pulmonary indices [27].…”

Section: Hsct For Systemic Lupus Erythematosus (Sle)mentioning

confidence: 96%